Asia

EMEA and GBEI brought China, Malaysia, Japan and India together to map an Asian brain economy strategy, framing brain capital as core economic infrastructure and introducing the Asian Brain Economy Index. #BrainEconomy #BrainCapital #Asia #BrainHealth

Alec Morton of NUS explains how AI is changing health technology assessment, what stays human, and why cheaper analysis could mean more health economics.

South Korea is putting AI at the centre of its healthcare agenda, pairing the new AI Basic Healthcare Strategy with a USD 30.4 billion biohealth export target. Vice Minister Lee Hyung Hoon sets out the vision in an interview with PharmaBoardroom. #SyenzaNews #SouthKorea #Biohealth #DigitalHealth #MarketAccess

🧬 Could a quantum-powered blood test detect Alzheimer’s years earlier? This breakthrough combines advanced quantum sensing with a simple blood draw to identify the disease at its earliest stages, opening new doors for timely intervention and care. Explore how this innovation could reshape diagnostics. #SyenzaNews #biotechnology #precisionmedicine #innovation #ai

🚀 What sparked China's pharmaceutical innovation surge after 2016? Key regulatory reforms streamlined approvals and accelerated R&D, rapidly elevating the country’s role in global drug development. Explore the data and trends behind this transformation. #SyenzaNews #pharmaceuticals #drugdevelopment #innovation #MarketAccess

🚀 What if smarter regulations could fast-track digital medical device approvals? Recent updates are streamlining pathways for MedTech innovators, cutting timelines while maintaining rigorous safety standards. This shift is accelerating patient access to next-generation health technologies. Read the full analysis to see what it means for your pipeline. #SyenzaNews #medicaldevices #regulatoryaffairs #innovation #DigitalTransformation

📈 How is Celltrion turning biosimilar momentum into stronger margins? The company’s Q2 results highlight robust growth across its biosimilar portfolio, driving improved profitability and reinforcing its competitive edge in global markets. Discover the full financial breakdown and strategic implications. #SyenzaNews #biotechnology #pharmaceuticals #innovation #MarketAccess

Could CAR‑T be the next breakthrough for advanced gastric cancer? 🔬 This article summarizes emerging CAR‑T approaches for gastric cancer—reviewing early clinical signals, promising antigen targets and combination strategies—while clearly outlining key hurdles (tumor microenvironment, safety, manufacturing and access). It’s a concise guide for clinicians, researchers and payers on the translational roadmap ahead. Read the full analysis to see which strategies are most promising and what’s needed to bring CAR‑T to patients with advanced gastric cancer. #SyenzaNews #oncology #precisionmedicine #innovation #MarketAccess

Can AI make skin cancer detection fairer across skin tones? 🩺🤖 A lesion-attention AI model that focuses on the lesion area reduces diagnostic bias and improves accuracy for darker skin tones while maintaining overall performance, offering a practical step toward more equitable dermatology tools. The paper details model design, evaluation on diverse datasets, and implications for clinical deployment. Read the full article to explore the methods, results, and what this means for clinicians, developers, and policymakers. #SyenzaNews #medicalimaging #AIinHealthcare #ai #innovation

Who should drive oncology market access — and how do you align them to speed patient access? 🤝🎯 This article lays out a practical multistakeholder strategy for oncology market access, emphasizing early payer and HTA engagement, real‑world evidence, patient‑centred value frameworks, and coordinated pricing and reimbursement approaches to balance innovation with system sustainability. Read the full piece to get actionable steps and real-world examples for aligning industry, payers, clinicians, and patients. #SyenzaNews #oncology #HealthEconomics #MarketAccess #healthcarepolicy

Is cancer quietly draining productivity across Asia‑Pacific? 💼📉 This analysis highlights large productivity losses driven by late diagnosis, unequal access to treatment, and weak return‑to‑work support — with sharp disparities between countries and industries. Tackling screening, survivorship care and employer‑led reintegration could recover economic value and improve patient outcomes. Read the full article for country comparisons and practical policy and employer actions. #SyenzaNews #oncology #HealthEconomics #healthcarepolicy #resourceallocation

Can a new India partnership make semaglutide affordable and scalable for millions with type 2 diabetes? 💊🤝 A strategic collaboration is aiming to localize production, accelerate regulatory pathways, and reduce prices so more patients across India can access this effective diabetes therapy. The move could reshape treatment availability and inform market-access strategies in other emerging markets. Read the full analysis to understand the implications for manufacturers, payers, and policy makers. #SyenzaNews #pharmaceuticals #globalhealth #MarketAccess #healthcarepolicy